CN112545909B - Theaflavin composition and application thereof - Google Patents
Theaflavin composition and application thereof Download PDFInfo
- Publication number
- CN112545909B CN112545909B CN202011466463.9A CN202011466463A CN112545909B CN 112545909 B CN112545909 B CN 112545909B CN 202011466463 A CN202011466463 A CN 202011466463A CN 112545909 B CN112545909 B CN 112545909B
- Authority
- CN
- China
- Prior art keywords
- theaflavin
- gallate
- skin care
- care product
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000014620 theaflavin Nutrition 0.000 title claims abstract description 87
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title claims abstract description 83
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 title claims abstract description 83
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title claims abstract description 83
- 229940026509 theaflavin Drugs 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 claims abstract description 82
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 claims abstract description 82
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 claims abstract description 63
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 claims abstract description 63
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 claims abstract description 63
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 26
- 230000008845 photoaging Effects 0.000 claims abstract description 25
- 230000005855 radiation Effects 0.000 claims abstract description 23
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000007900 theaflavin-3-gallate Nutrition 0.000 claims abstract description 19
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- ZEASWHWETFMWCV-UHFFFAOYSA-N 7-O-(2-O-Acetyl-6-O-Methyl-beta-D-glucuronoside)-4',5,7-Trihydroxyflavone Natural products C=1C(O)=C(O)C2=C(O)C(=O)C=C(C3C(CC4=C(O)C=C(O)C=C4O3)OC(=O)C=3C=C(O)C(O)=C(O)C=3)C=C2C=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006174 pH buffer Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 29
- 108090000790 Enzymes Proteins 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract description 4
- 230000004792 oxidative damage Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 239000000047 product Substances 0.000 description 26
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 23
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 23
- 229940030275 epigallocatechin gallate Drugs 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 20
- 244000269722 Thea sinensis Species 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 235000013616 tea Nutrition 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 3
- 102000001284 I-kappa-B kinase Human genes 0.000 description 3
- 108060006678 I-kappa-B kinase Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000006750 UV protection Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000010001 cellular homeostasis Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- FJYGFTHLNNSVPY-BBXLVSEPSA-N theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 description 2
- 235000008118 thearubigins Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VJPAMLCBTIWAHI-UHFFFAOYSA-N benzo[7]annulen-7-one Chemical compound C1=CC(=O)C=CC2=CC=CC=C21 VJPAMLCBTIWAHI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 108091006003 carbonylated proteins Proteins 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- DZGQZNRJDFZFLV-UHFFFAOYSA-N theaflavin 3,3'-digallate Natural products OC1=CC(=Cc2cc(C3Oc4cc(O)cc(O)c4CC3OC(=O)c5cc(O)c(O)c(O)c5)c(O)c(O)c2C1=O)C6Oc7cc(O)cc(O)c7CC6OC(=O)c8cc(O)c(O)c(O)c8 DZGQZNRJDFZFLV-UHFFFAOYSA-N 0.000 description 1
- 235000008230 theaflavin-3,3'-digallate Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
Abstract
A theaflavin composition comprising: theaflavin-3' -gallate; or separating mixture of theaflavin-3'-gallate and one or more of theaflavin, theaflavin-3-gallate or theaflavin-3, 3' -gallate; alternatively, salt or derivative, hydrate or solvate of theaflavin-3' -gallate can be obtained in the field of skin care products; and a skin care product carrier or a pharmaceutically acceptable carrier. The theaflavin composition can improve the activity of antioxidant enzyme, reduce the content of MDA and ROS, repair mitochondrial membrane potential to a certain extent, and further reduce oxidative damage of UVB radiation to cells, thereby resisting photoaging damage of ultraviolet radiation to human skin. On the other hand, theaflavin-3-gallate TF3' G can effectively inhibit inflammatory reaction caused by UVB radiation and reduce the generation of aggregates in HaCaT cells, and has wide prospect for preparing skin care products or medicines for preventing photoaging.
Description
Technical Field
The invention relates to the application field of tea pigments, in particular to a theaflavin composition and application thereof.
Background
The tea pigment is a water-soluble pigment mixture derived from oxidation of polyphenol compounds mainly comprising catechin in tea, and comprises theaflavin, thearubigin and theabrownin. Among them, Theaflavins (Theaflavins, TFs) are the core functional component of black tea, and are called "soft gold" in tea. The theaflavin is a structural compound of the benzo-tropone which is soluble in ethyl acetate, contains a plurality of phenolic hydroxyl groups and is orange yellow and is generated by the phenylpropyl cyclization of catechin through an enzymatic reaction, is an important quality component and a functional component of black tea, and comprises 4 main monomer components of theaflavin (theaflavin), theaflavin-3-gallate (theaflavin-3-gallate), theaflavin-3' -gallate (theaflavin-3 ' -gallate) and theaflavin digallate (theaflavin-3, 3' -digallate), wherein the structural general formula of the theaflavin is shown in the attached figure 1: wherein, in the attached figure 1, R1 ═ R2 ═ H represents Theaflavin (TF); r1 ═ H, R2 ═ galloyl, and represents theaflavin-3'-gallate (TF3' G); r2 ═ H, R1 ═ galloyl, for theaflavin-3-gallate (TF 3G); r1 ═ galloyl, R2 ═ galloyl, and stands for theaflavin-3, 3' -gallate (TFDG).
Although green tea and EGCG have strong reducing power, they are also strong in promoting oxidation. Theaflavins have more conjugation and phenolic quinone equilibrium than catechins and are more easily deprotonated and act to scavenge free radicals. Also, unpaired electrons on the oxygen atom of the protonated phenoxy radical are dispersed throughout the conjugated system and become stable radicals, thereby reducing the activity of the radical. According to the experimental data, the balance of conjugated pi bonds and benzoquinone is probably the core functional structure of TF3' G, and the method has high efficiency and low toxicity.
Skin aging includes photoaging and intrinsic aging, which are mutually promoted, resulting in a series of aging phenomena, such as skin roughness, sagging, increased spots and wrinkles. After intrinsic aging of the skin, the barrier function of Ultraviolet (UV) light will be reduced, which is prone to photoaging. About 90% of skin aging is mainly caused by photoaging. Anti-photoaging plays a key role in skin protection.
The ultraviolet rays are divided into 3 bands, long-wave ultraviolet rays UVA, medium-wave ultraviolet rays UVB, and short-wave ultraviolet rays UVC. Wherein UVB has stronger energy and weaker penetrating power, mainly damages epidermal cells, destroys skin barriers, inhibits the immune function, causes erythema and pigmentation, and has the skin damage capability about 1000 times of UVA. Keratinocytes, also called epithelial cells, located on the top layer of human skin, account for 95% of the epidermal cells, are an important barrier to protect the body from the external environment, and are the main sensitive target cells for Ultraviolet (UV) irradiation. During epidermal differentiation, keratinocytes continue to produce lipids and excrete cells, forming an extracellular lipid-rich layer, mainly comprising ceramides, free fatty acids and cholesterol. Skin photoaging is the result of the combined effects of UVB and UVA.
CN _103478336_ A high-activity tea pigment, its extraction method and application disclose a high-activity tea pigment, which comprises 50-90% of theabrownin, 7-30% of theaflavin and 3-20% of thearubigin. The extraction method comprises cross-linking glucose oxidase to nanoscale Fe304, and adding CO2And inert material Al z03 to form an enzyme mixture; B. pulverizing folium Camelliae sinensis, adding water, heating to boil, standing, cooling, and filtering to obtain tea soup; C. mixing the enzyme mixture with the tea soup, and circularly heating and cooling; D. circularly heating and cooling for 12-48 hours, putting the magnet into a container, sucking supernatant and filtering; E. evaporating the filtrate to obtainDissolving the crude extract with alcohol water solution, concentrating, and drying to obtain high-activity tea pigment. The high-activity tea pigment can be used in food. At present, the research on theaflavin mainly focuses on the antioxidation, and the research reports of the application of theaflavin in the fields of ultraviolet resistance, anti-inflammation and the like are rarely seen, so that the method has obvious significance on how to efficiently apply theaflavin to the prevention of photoaging caused by ultraviolet.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: overcomes the defects of the prior art, and provides a theaflavin composition with good ultraviolet resistance effect and application thereof.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a theaflavin composition comprising: theaflavin-3'-gallate (TF3' G); or separating mixture of theaflavin-3' -gallate (TF3' G) and one or more of Theaflavin (TF), theaflavin-3-gallate (TF3G) or theaflavin-3, 3' -gallate (TFDG); or the salt or derivative, hydrate or solvate of theaflavin-3' -gallate can be obtained in the field of skin care products,
and a skin care product carrier or a pharmaceutically acceptable carrier.
In an exemplary embodiment, the concentration of theaflavin-3' -gallate (TF3' G, theaflavin-3' -gallate) is 0.1 μ M or greater.
Further, the concentration of theaflavin-3'-gallate TF3' G is 0.1 to 40. mu.M, preferably, the concentration of theaflavin-3'-gallate TF3' G is 0.25 to 20. mu.M.
Further, the theaflavin composition is in the form of aqua, lotion, ointment or cream.
Further, the skin care product carrier comprises a liquid carrier, an excipient, an agent or a combination thereof.
Further, the liquid carrier includes water, saline solution, aqueous dextrose solution, glycerol solution, or combinations thereof.
Further, the excipient includes starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, ethanol or a combination thereof.
Further, the agent includes a wetting agent, a stabilizer, an emulsifier, a pH buffer, a thickener, a lubricant, a colorant, or a combination thereof.
The technical scheme adopted by the invention for solving the other technical problem is as follows:
the application of theaflavin composition in preparing skin care products or medicines for preventing photoaging.
The application refers to the application of the theaflavin in preparing a skin care product for skin photoaging caused by ultraviolet radiation.
The application refers to the application of the theaflavin in preparing skin care products or medicines for inhibiting inflammatory reaction caused by ultraviolet radiation.
The theaflavin composition has the beneficial effects that:
the theaflavin composition has relatively single component, is easy to prepare and separate, and has low preparation cost.
The theaflavin composition can improve the activity of antioxidant enzyme, reduce the content of MDA and ROS, repair mitochondrial membrane potential to a certain extent, and further reduce oxidative damage of UVB radiation to cells, thereby resisting photoaging damage of ultraviolet radiation to human skin. On the other hand, theaflavin-3'-gallate TF3' G can effectively inhibit inflammatory reaction caused by UVB radiation and reduce the generation of accumulation in HaCaT cells, and has wide prospect for preparing skin care products or medicines for preventing photoaging.
Drawings
FIG. 1-is the chemical structural formula of theaflavin;
FIG. 2 is the structural formula of theaflavin-3'-gallate (TF3' G) and epigallocatechin gallate (EGCG) as the active ingredients of a theaflavin composition and the ultraviolet-visible light absorption spectrum thereof;
FIG. 3 is a photograph of white light and SEM scan analysis of the placebo group, UVB treatment model group, TF3' G treatment group according to the present invention;
FIG. 4 is a graph showing the comparative analysis of the cell viability of the 4 monomeric components of theaflavins and EGCG-treated group in example 1;
FIG. 5 is a graph showing the comparative analysis of early apoptosis and late apoptosis of theaflavin-3'-gallate (TF3' G) which is the active ingredient of a theaflavin composition according to example 1, and EGCG-treated group;
FIG. 6 is a graph showing ROS content analysis of the active ingredient theaflavin-3'-gallate (TF3' G) treatment group of one of the theaflavin compositions of example 1;
FIG. 7 is a graph of Rh123 staining analysis of mitochondrial membrane potential analysis of the active ingredient theaflavin-3'-gallate (TF3' G) treated group of one of the theaflavin compositions of example 1;
FIG. 8 is a graph showing the MDA content measurement analysis of the active ingredient theaflavin-3'-gallate (TF3' G) treated group of one of the theaflavin compositions of example 1;
FIG. 9 is a graph showing the activity assay of intracellular GSH-Px, CAT and SOD antioxidase enzymes in the active ingredient theaflavin-3'-gallate (TF3' G) treated group of one of the theaflavin compositions of example 1;
FIG. 10-Western-blotting analysis of the active ingredient theaflavin-3'-gallate (TF3' G) treatment group NF-. kappa. B, I. kappa.Balpha., p-IkappaBalpha., IKK. beta., p-IKK. beta., and IL-6 expression of one of the theaflavin compositions of example 1, wherein, # p <0.05, # p <0.01, vs. blank control; p <0.05, p <0.01 vs UVB treatment model set, n-3;
FIG. 11-is a graph showing the IR spectrum analysis of the active ingredient theaflavin-3'-gallate (TF3' G) treated group and EGCG treated group of a theaflavin composition according to example 1 (note: IR fingerprint of cell lipid fraction (FIG. 11a), IR fingerprint of cell protein fraction (FIG. 11b), IR fingerprint of cell nucleic acid fraction (FIG. 11c), and IR fingerprint of cell carbohydrate fraction (FIG. 11 d));
FIG. 12 is a Western blotting analysis chart of aggregate formation of cells of theaflavin-3'-gallate (TF3' G) treated group, blank control group, UVB treated model group as an active ingredient of a theaflavin composition of example 1, wherein # p <0.05, # p <0.01, vs. control group; p <0.05, p <0.01 vs UVB group, n-3.
Detailed Description
The invention is further explained with reference to the drawings and the embodiments.
Example 1
A theaflavin composition comprises theaflavin-3' -gallate,
and a skin care product carrier or a pharmaceutically acceptable carrier.
The concentration of the theaflavin-3' -gallate (TF3' G, theaflavin-3' -gallate) is 0.1-40 mu M.
The theaflavin composition is in the form of aqua, lotion, ointment or cream.
The skin care product carrier comprises a liquid carrier, an excipient, an agent or a combination thereof.
The liquid carrier comprises water, saline solution, aqueous dextrose solution, glycerol solution, or combinations thereof.
The excipient comprises starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, ethanol or a combination thereof.
The agents include wetting agents, stabilizers, emulsifiers, pH buffers, thickeners, lubricants, colorants, or combinations thereof.
The efficacy analysis of a theaflavin composition of this example includes the following:
analytical model construction
HaCaT cells (ordered from the China center for type culture Collection) were cultured in MEM medium containing 10% fetal bovine serum in a cell incubator at 37 ℃ and 5% CO 2. When the cells fused to 90%, the cells were digested with 0.5% trypsin and subculture was continued.
HaCaT cells were treated as 104The density of individual cells/well was seeded in 96-well cell culture plates and cultured in a cell incubator for 24 h. Will be provided withThe cells were divided into a blank control group (CTR), a UVB treatment model group (UVB), a TF3'G treatment group and a UVB irradiation treatment group pre-incubated with EGCG (epigallocatechin gallate), the blank control group and the model group were changed to normal medium, the TF3' G treatment group and the EGCG treatment group were changed to medium of different concentrations (0.1. mu.M, 0.25. mu.M, 0.5. mu.M, 1. mu.M, 5. mu.M, 10. mu.M, 20. mu.M, 40. mu.M), the culture was continued in a cell culture incubator for 6 hours, then the medium was discarded, a small amount of PBS was added, the blank control group was covered with an aluminum foil sheet, the cell culture plate was placed in an ultraviolet crosslinking apparatus at a set strength of 60mJ/cm2, after irradiation, the medium was changed to normal medium, and the cells were continued to be cultured.
Corresponding processing and analysis are carried out on the constructed model group, and the result is as follows:
1) analysis of ultraviolet and visible light absorption and ultraviolet treatment of cell loss of tea composition flavin active ingredient TF3' G and EGCG
As can be seen from FIG. 2, compared with EGCG, the conjugated system space of the benzotropolone structure in the molecular structure of TF3' G is larger, and the conjugated system has more phenolic hydroxyl structures. The ultraviolet full-waveband scanning result shows that TF3'G has a stronger absorption peak at 280nm compared with EGCG under the same molar concentration level, and TF3' G also has a remarkable absorption peak at 368 nm. Therefore, TF3' G is presumed to have certain absorption effect on UVB and UVA, and the effect is better than that of EGCG.
Referring to fig. 3, the scanning electron microscope experimental results show that: compared with a control group, after UVB treatment, cells of the UVB treatment model group collapse, a pore structure appears on the surface, and a striae structure disappears; the TF3' G treated group was full of cells, rich in cell surface striae structure and luster, and consistent with the control group.
2) Analysis of the Effect of theaflavin-3'-gallate (TF3' G) on maintaining cellular homeostasis
Firstly, MTT method for detecting cell activity
After further culturing the cells for 24 hours by irradiation with UVB, the cell culture medium was changed to MEM containing 0.5mg/mL MTT, and 5% CO was added at 37 ℃2Culturing for 4h under concentration conditions, aspirating the medium, adding 150. mu.L DMSO into each well, and incubatingThe mixture was shaken at room temperature for 10min (37 ℃ C., 100rpm), and the absorbance of each well was measured with a multifunction microplate reader at a detection wavelength of 570 nm. The calculation formula is as follows: vCell viability＝ODSample(s)/ODBlank spaceX 100%, the results are shown in FIG. 4.
As can be seen from fig. 4, the cell viability of the UVB-treated model group was significantly decreased after UVB irradiation compared to the control group; EGCG, TF, TF3G, TF3' G and TFDG in
The concentration range of (A) inhibits the cell viability reduction induced by UV, the EC50 is respectively 1.894 mu M, 1.295 mu M, 0.522 mu M, 0.483 mu M and 0.584 mu M, and each treatment group has the effect of obviously inhibiting HaCaT injury caused by UVB in a dose-dependent manner; TF3' G was found to have an improved effect on maintaining cellular homeostasis over EGCG, with the best inhibition of UVB radiation-induced cell viability decline relative to the other 3 theaflavin monomers.
Based on the above results, in order to prove whether TF3' G has side effects of promoting oxidation while having high activity, the following experiments on preventing photoaging with TF3' G were carried out using four concentrations (5. mu.M, 10. mu.M, 20. mu.M, 40. mu.M) of TF3' G.
② Annexin V-FITC staining for detecting cell apoptosis
Referring to fig. 5, early and late apoptosis of cells was analyzed using Annexin V-FITC/PI apoptosis staining, and green fluorescence and red fluorescence of cells of UVB-treated model group were significantly enhanced compared to control group (CTR), in which red fluorescence staining rate was denser; the TF3' G-treated group had increased green and red fluorescence values relative to the control group and decreased in concentration-dependence (i.e., 10 μ M of the TF3' G-treated group had green and red fluorescence values weaker than 5 μ M of the TF3' G-treated group); the result shows that after UVB irradiation, the cell undergoes early and late apoptosis, the late apoptosis cell is more obvious, and TF3' G has the effect of obviously inhibiting UVB induced apoptosis.
3) Analysis of oxidative stress of theaflavin-3'-gallate (TF3' G) on inhibition of UVB-induced HaCaT cells
Analysis of intracellular ROS content
a) ROS content determination method
Cells were aligned at 5X 104Inoculating the density of each cell/well on a glass slide, culturing the cells according to the method for constructing the analysis model in the step 1), discarding the cell culture solution after the culture is finished, washing twice with PBS, adding 200 μ L of serum-free MEM culture medium containing 10 μmol/mL DCFH-DA (Muyuntian) into each well, and placing in CO2The culture was continued for 20min in the incubator, and after the completion of the culture, the residual DCFH-DA was completely removed by washing 3 times with serum-free MEM medium. Observing by using white light and green light under a fluorescence microscope, collecting images after white light is subjected to white balance, and calculating the ROS index according to the difference of average optical densities of different treatment groups, wherein the calculation formula is as follows: ROS index is fluorescence intensity/cell number.
b) ROS assay results analysis
From the white light photographing result of fig. 6, it can be seen that: compared with a control group, the UVB treatment model group has the advantages that the number of cells is reduced, the green fluorescence intensity is obviously enhanced, the UVB irradiation reduces the adherence of the cells, the intercellular space is increased, the shape is irregular, and the number is obviously reduced.
The change of intracellular ROS content detected by DCFH-DA showed a significant increase in the rate of positive staining of green fluorescence in cells of the UVB-treated model group compared to the control group, indicating a significant increase in free radicals in cells after UVB irradiation (p < 0.01). The positive staining rate of the TF3'G treatment group was significantly inhibited, indicating that TF3' G was able to significantly reduce UVB-induced increases in intracellular Reactive Oxygen Species (ROS) levels; moreover, when the concentration of the theaflavin-3-gallate TF3' G is more than 20 mu M, the influence of the continuous increase of the concentration of the theaflavin-3' -gallate TF3' G on the level of Reactive Oxygen Species (ROS) in the cells tends to be flat.
The rhodamine 123 staining results are shown in fig. 7: compared with a control group, the yellow-green fluorescence intensity of the cells of the UVB treatment model group is obviously increased, and TF3' G has a concentration-dependent fluorescence enhancement inhibition effect. The results show that TF3' G can inhibit the effect of UVB on mitochondrial membrane potential reduction.
Measurement of antioxidase activity and MDA content
a) Method for measuring activity of antioxidant enzyme and MDA content
Inoculating cells into a 6-well plate, culturing the cells according to the method in the analysis model construction in the step 1), collecting cell proteins by using RIPA lysate after the culture is finished, determining the protein concentration by using a BCA kit (Thermo), and determining the activities of SOD, CAT, GSH-Px and LDH and the content of MDA (Nanjing construction) in the cells strictly according to the method of the kit.
b) Determination result and analysis of antioxidant enzyme activity and MDA content
Referring to fig. 8 and 9, compared with the blank control group, the UVB treatment model group has increased MDA content and decreased enzymatic activities (p <0.01) such as antioxidant-related SOD, CAT and GSH-Px, which indicates that UVB radiation can significantly reduce the intracellular antioxidant enzymatic activity and promote the generation of oxidation products;
the TF3' G treated group reduced MDA content and promoted activities of SOD, CAT and GSH-Px enzymes compared to the model group; the activity of SOD/CAT and GSH-Px is obviously increased along with the increase of the concentration of theaflavin-3' -gallate TF3' G medicine, when the concentration of theaflavin-3' -gallate TF3' G is more than 20M, the difference between the activity of CAT of cells treated by the theaflavin-3' -gallate TF3' and a UVB treatment model group is obvious, and the change amplitude of the difference tends to be flat along with the increase of the concentration of theaflavin-3-gallate TF3' G; the MDA content is obviously reduced along with the increase of the concentration of theaflavin-3' -gallate TF3' G medicine, and the reduction amplitude is reduced along with the increase of the concentration of theaflavin-3' -gallate TF3' G, so that TF3' G can obviously improve the endogenous antioxidant capacity and reduce cell damage.
4) Theaflavin-3'-gallate (TF3' G) inhibits UVB-induced activation of NF- κ B inflammatory pathway in HaCaT cells
TF3' G treatment group: HaCaT cells are treated with TF3' G (5 mu M,10 mu M,20 mu M,40 mu M) for 6h, irradiated with UVB (60mJ/cm2), cultured for 24h, detected by a Western blot method for expression of NF-kappa B, p-I kappa B alpha and I kappa B alpha, p-IKK beta and IKK beta proteins, and analyzed quantitatively by Western blot of relative protein content.
Referring to fig. 10, compared to the control group, the phosphorylation levels of IKK β and ikb α of the HaCaT cells after UVB irradiation in the UVB-treated model group were increased, the nuclear translocation expression of NF- κ B was promoted, and the expression level of the proinflammatory factor IL-6 was increased. IKK beta phosphorylation can further induce I kappa B alpha phosphorylation, so that NF-kappa B is separated from I kappa B alpha, nuclear transfer of a transcription factor NF-kappa B is promoted, and the expression of IL-6 is increased.
The TF3'G treatment group can obviously interfere the activation of a UVB-induced cell NF-kB inflammatory pathway and reduce the expression of IL-6, thereby also defining one of the potential action mechanisms of TF3' G for potentially inhibiting UVB-induced cell photoaging, namely inhibiting the UVB-induced activation of the NF-kB inflammatory pathway of HaCaT cells.
5) Theaflavin-3'-gallate TF3' G inhibits UVB-induced formation of HaCaT cell protein aggregates
Infrared spectrum analysis of the blank control group, the UVB treatment model group, the EGCG treatment group and the TF3'G treatment group refers to fig. 11, detection is carried out by using an infrared spectrum technology, and the cell infrared spectrum after treatment of the blank control group, the UVB treatment model group, the EGCG treatment group and the TF3' G treatment group is obtained: 3000-2800 cm-1The absorption band generated is mainly characterized by the C-H bond of long-chain fatty acids, the intensity of this region being closely related to the lipid content (FIG. 11a), 3012cm-1Characterization of the absorption band v ═ C-H from unsaturated fatty acids, 1740cm-1The absorption band is mainly generated by stretching of ester groups of phospholipids; 1700-1500cm-1The regions are amide I band and amide II band, mainly protein absorption peak (absorption peak marked b in FIG. 11); 1300-1000 cm-1The band can measure the nucleic acid and polysaccharide structures (the absorption peak marked by c in FIG. 11 and the absorption peak marked by d in FIG. 11) at 1300-1180 cm-1Closely related to nucleic acid structure, 1180-1020 cm-1Bands then allow measurement of sugar content.
After the cells are irradiated by UVB, the infrared spectrum of the cells in the UVB treatment model group is shifted to a low wavelength band compared with that in a blank control group, and the peak intensity is changed. At 3000-2800 cm-1In the fatty acid absorption peak of (2), the peak height and the peak width are both increased, especially for unsaturated fatty acids
The intensity of the ν -CH peak increases significantly and a distinct splitting peak occurs; peak of C ═ O relative phospholipid at-1740 cm-1Is stretched. These results imply fatAnd increased phospholipid content and altered structure. 1740cm-1The peak intensity of the characteristic peak is increased to a certain extent, and an amide I band and an amide II band (1700-1500 cm)-1) The peak intensity decreases and shifts to the lower band. 1230-1080 cm-1The absorption peak of (A) is obviously enhanced, and an obvious splitting peak appears, which indicates that the structure and the content of the polysaccharide (especially nucleic acid) are greatly changed. These results show that: cellular biomacromolecule lipid, protein, nucleic acid and polysaccharide structures or contents are changed to different degrees. Literature studies indicate that after uv irradiation, the level of long-chain ceramides and glycerolipid species of keratinocytes are significantly increased; lipid bilayers also change, increasing phospholipid content;
the cleavage peaks of fatty acid and nucleic acid are eliminated in the EGCG and TF ' 3G treatment group, and the EGCG treatment group and the TF3' G treatment group can obviously inhibit the change of the absorption peaks, and are consistent with the blank control group, so that the EGCG and TF3' G group can protect the cellular biological macromolecular structure.
In the amide I band and the amide II band (1700-1500 cm)-1) The zones are enlarged as shown in the upper left corner of fig. 11, and the UVB treatment model group absorbs a significant decrease in peak intensity and shifts to a peak with a lower number of wavelengths as compared to the control group, i.e., uv irradiation may increase the formation of cytotoxic proteins (e.g., carbonylated proteins).
The EGCG treatment group and the TF3' G treatment group can inhibit the infrared spectrum at 1700-1500cm-1The range is changed, and TF3' G has better effect than EGCG, and EGCG and TF3' G obviously inhibit the change trend of absorption peaks, particularly TF3' G, and have better peak shape than the control group.
(ii) Western-blotting analysis of formation of aggregates
HaCaT cells were treated with TF3' G (5. mu.M, 10. mu.M, 20. mu.M, 40. mu.M) for 6 hours, irradiated with UVB (60mJ/cm2), cultured for 24 hours, and assayed for 4-HNE, UPs, P62, and RAGE protein expression by Western blot, as shown in FIG. 12.
Referring to FIG. 12, significant increases in intracellular p62, RAGE, UPs and 4-HNE oxidized protein (p <0.01) in UVB-treated HaCaT cells indicate increased protein carbonylation and cytotoxic aggregate formation and decreased autophagy function following UV irradiation. After TF3' G treatment group had been treated with TF3' G, the expression levels of 4-HNE, UPS, RAGE and P62 in HaCaT cells were all significantly reduced compared to the UVB treatment model group, i.e., TF3' G significantly reduced the formation of cytotoxic proteins and inhibited their pathways (P <0.01)
As the skin is photoaged and is also related to the formation of advanced glycosylation end products AGEs, after the AGEs are combined with a receptor RAGE, cells can be promoted to generate more aggregates, and therefore, the theaflavin-3'-gallate TF3' G can effectively inhibit the formation of UVB-induced HaCaT cell protein aggregates, thereby preventing the skin from photoaging.
The application of the theaflavin composition of the embodiment is to prepare the skin care product for preventing photoaging.
Example 2
A theaflavin composition of this example comprises 4 monomer mixtures of theaflavin-3'-gallate and theaflavin, theaflavin-3-gallate or theaflavin-3, 3' -gallate,
and a skin care product carrier or a pharmaceutically acceptable carrier.
The concentration of the theaflavin-3-gallate (TF3' G, theaflavin-3-gallate) is 0.5 mu M, and the mass ratio of the mixture of the theaflavin-3' -gallate and 4 monomers of theaflavin, theaflavin-3-gallate or theaflavin-3, 3' -gallate in the composition is 0.05-2.0%.
The theaflavin composition is in the form of aqua, lotion, ointment or cream.
The skin care product carrier comprises a liquid carrier, an excipient, an agent or a combination thereof.
The liquid carrier comprises water, saline solution, aqueous dextrose solution, glycerol solution, or combinations thereof.
The excipient comprises starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, ethanol or a combination thereof.
The agents include wetting agents, stabilizers, emulsifiers, pH buffers, thickeners, lubricants, colorants, or combinations thereof.
The application of the theaflavin composition of the embodiment refers to the application of the theaflavin in preparing skin care products for preventing photoaging, in particular to the application of the theaflavin in preparing skin care products for preventing photoaging of skin caused by ultraviolet radiation, or the application of the theaflavin in preparing skin care products or medicines for inhibiting inflammatory reaction caused by ultraviolet radiation.
Example 3
A theaflavin composition comprises salt or derivative, hydrate or solvate of theaflavin-3' -gallate obtained from skin care product field,
and a skin care product carrier or a pharmaceutically acceptable carrier.
The concentration of the salt, the derivative, the hydrate or the solvent compound of the theaflavin-3-gallate (TF3' G, theaflavin-3' -gallate) is 0.25-20 mu M, and the mass ratio of the salt, the derivative, the hydrate or the solvent compound of the theaflavin-3' -gallate to the composition is 0.05-2%.
The carrier of the skin care product or the pharmaceutically acceptable carrier of the theaflavin composition of this example is the same as example 1.
The application of the theaflavin composition of the embodiment is to prepare a skin care product for preventing photoaging, and specifically, the theaflavin is used for preparing a skin care product for preventing photoaging of skin caused by ultraviolet radiation, or the theaflavin is used for preparing a skin care product or a medicine for inhibiting inflammatory reaction caused by ultraviolet radiation.
The theaflavin composition can also be a mixture of theaflavin-3' -gallate and theaflavin according to the mass ratio of 1: 1, and a skin care product carrier or a pharmaceutically acceptable carrier; or, the mixture of theaflavin-3' -gallate and theaflavin, theaflavin-3-gallate according to the mass ratio of 3: 1, and skin care product carrier or pharmaceutically acceptable carrier; or the mixture of theaflavin-3'-gallate and theaflavin-3, 3' -gallate according to the mass ratio of 2: 1, and skin care product carrier or pharmaceutically acceptable carrier.
In addition, according to the anti-ultraviolet or anti-inflammatory effect to be achieved, the concentration of the theaflavin-3' -gallate, or the separation mixture of the theaflavin-3' -gallate and one or more of theaflavin, theaflavin-3-gallate or theaflavin-3, 3' -gallate or the salt or derivative, hydrate or solvate of the theaflavin-3' -gallate obtained in the field of skin care products can be properly adjusted to be more than 0.1 μ M, for example, the concentration of the theaflavin-3' -gallate is preferably 0.5 to 10 μ M when the anti-ultraviolet effect reaches 50%; if the ultraviolet resistance effect is 70%, the concentration of the theaflavin-3' -gallate is preferably 10-20 mu M; the above technical features can be understood and implemented by those skilled in the art through the text description, and therefore, the accompanying drawings are not needed to be described.
Claims (7)
1. The application of theaflavin composition in preparing skin care products for skin photoaging caused by ultraviolet radiation is characterized in that,
the theaflavin composition can inhibit skin aging caused by ultraviolet radiation by reducing the expression level of proinflammatory factor IL-6 and reducing the generation of intracellular aggregates; the theaflavin composition is selected from any one of the following:
1) the theaflavin composition comprises: theaflavin-3' -gallate, and a skin care product carrier; the concentration of theaflavin-3' -gallate is more than or equal to 0.1 mu M;
2) the theaflavin composition comprises: one or more of theaflavin, theaflavin-3-gallate or theaflavin-3, 3'-gallate and mixture of theaflavin-3' -gallate, and skin care product carrier; the concentration of theaflavin-3' -gallate is more than or equal to 0.1 mu M;
3) the theaflavin composition comprises: the salt or derivative, hydrate or solvate of theaflavin-3' -gallate and skin care product carrier can be obtained in the field of skin care products; the concentration of the salt or the derivative, the hydrate or the solvent compound of the theaflavin-3' -gallate is 0.25-20 mu M.
2. The use of a theaflavin composition as set forth in claim 1 for the preparation of a skin care product for ultraviolet radiation induced skin photoaging wherein the concentration of theaflavin-3'-gallate TF3' G is 0.25-20 μ M.
3. Use of a theaflavin composition as defined in claim 1 or claim 2 for the preparation of a skin care product for the photo-aging of skin by ultraviolet radiation, wherein said theaflavin composition is in the form of a lotion, emulsion, ointment or cream.
4. Use of a theaflavin composition as set forth in claim 1 or 2 for the preparation of a skin care product for ultraviolet radiation induced skin photoaging wherein said skin care product carrier further comprises a liquid carrier.
5. Use of a theaflavin composition according to claim 4 for the preparation of a skin care product for ultraviolet radiation induced skin photoaging wherein said liquid carrier comprises water, saline solution, glycerin solution or a combination thereof.
6. Use of a theaflavin composition according to claim 1 for the preparation of a skin care product for ultraviolet radiation induced skin photoaging wherein said skin care product carrier further comprises a moisturizer, a stabilizer, an emulsifier, a pH buffer, a thickener, a lubricant, a colorant or a combination thereof.
7. Use of a theaflavin composition for the manufacture of a skin care product for inhibiting inflammatory response induced by ultraviolet radiation, wherein the theaflavin composition is selected from any one of the following:
1) the theaflavin composition comprises: theaflavin-3' -gallate, and a skin care product carrier or a pharmaceutically acceptable carrier; the concentration of theaflavin-3' -gallate is more than or equal to 0.1 mu M;
2) the theaflavin composition comprises: a mixture of theaflavin-3'-gallate and one or more of theaflavin, theaflavin-3-gallate or theaflavin-3, 3' -gallate, and a skin care product carrier or a pharmaceutically acceptable carrier; the concentration of theaflavin-3' -gallate is more than or equal to 0.1 mu M;
3) the theaflavin composition comprises: the salt or derivative, hydrate or solvate of theaflavin-3' -gallate and carrier of skin care product or pharmaceutically acceptable carrier can be obtained in the field of skin care product; the concentration of the salt or the derivative, the hydrate or the solvent compound of the theaflavin-3' -gallate is 0.25-20 mu M;
the theaflavin composition can inhibit inflammatory reaction caused by ultraviolet radiation by reducing expression level of proinflammatory factor IL-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011466463.9A CN112545909B (en) | 2020-12-14 | 2020-12-14 | Theaflavin composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011466463.9A CN112545909B (en) | 2020-12-14 | 2020-12-14 | Theaflavin composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112545909A CN112545909A (en) | 2021-03-26 |
| CN112545909B true CN112545909B (en) | 2022-06-21 |
Family
ID=75064399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011466463.9A Expired - Fee Related CN112545909B (en) | 2020-12-14 | 2020-12-14 | Theaflavin composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112545909B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113577055B (en) * | 2021-07-26 | 2022-10-04 | 安徽农业大学 | Theaflavin composition for promoting wound healing and preparation method and application thereof |
| CN113925168A (en) * | 2021-10-28 | 2022-01-14 | 湖北工业大学 | Application of EGCG quinone as inhibitor for resisting AGEs (angiotensin-converting enzyme) release in gastrointestinal tract |
| CN116135209A (en) * | 2021-11-16 | 2023-05-19 | 湖南农业大学 | Composition for inhibiting betA-Amyloid toxic stress and promoting neurite growth of nerve cells and application thereof |
| CN113951328A (en) * | 2021-11-30 | 2022-01-21 | 北安宜品努卡乳业有限公司 | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102970961A (en) * | 2010-04-06 | 2013-03-13 | 荷兰联合利华有限公司 | A personal care composition |
| CN106924242A (en) * | 2017-04-12 | 2017-07-07 | 中山大学 | The purposes of the composition comprising theaflavih digallate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102428987B1 (en) * | 2017-05-16 | 2022-08-04 | (주)아모레퍼시픽 | Composition Containing Extracts of Camellia sinensis |
-
2020
- 2020-12-14 CN CN202011466463.9A patent/CN112545909B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102970961A (en) * | 2010-04-06 | 2013-03-13 | 荷兰联合利华有限公司 | A personal care composition |
| CN106924242A (en) * | 2017-04-12 | 2017-07-07 | 中山大学 | The purposes of the composition comprising theaflavih digallate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112545909A (en) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112545909B (en) | Theaflavin composition and application thereof | |
| KR101819727B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
| US20100015071A1 (en) | Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol as an Active Ingredient | |
| KR101983041B1 (en) | Fermentation method of lactic acid bacteria using berry and its use | |
| US20100099698A1 (en) | Compositions for Improving Skin Conditions Comprising Matrine or Its Oxidized Derivatives | |
| KR101315346B1 (en) | Compositions for Improving Skin Conditions Using an Extract of Stichopus japonicus Red | |
| KR102068736B1 (en) | A cosmetic composition for anti-aging comprising extract of coffee grounds | |
| WO2015186962A1 (en) | Composition for alleviating atopic dermatitis, using fermented green tea extract | |
| KR20110085151A (en) | Megastigmane derivatives isolated from ilex paraguariensis, preparation method thereof and anti-wrinkle composition containing the same as an active ingredient | |
| KR102501047B1 (en) | Cosmetic composition helping in improving water content in corneous lower layer comprising the extract of natural products | |
| KR101546336B1 (en) | Composition for Preventing Skin aging Using Enzyme Treatments of Citrus sunki Rind and Those Extracts | |
| KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
| KR20190036975A (en) | Compositions for Improving Skin Wrinkles and Skin Whitening Using an Extract of Polygonum japonica | |
| KR101546335B1 (en) | Composition for Preventing Skin Wrinkle Using Enzyme Treatments of Citrus sunki Rind and Those Extracts | |
| KR20130027227A (en) | Citrus flower compositions for improving skin conditions | |
| KR20070111025A (en) | Anti-wrinkle cosmetic compositions comprising the extract of phaseolus radiatus as active ingredient | |
| KR101878871B1 (en) | Composition for Improving Skin Wrinkles Using an Extract of Dipterocarpus intricatus | |
| KR20110087363A (en) | Cosmetic composition comprising the extract of adenocaulon himalaicum as active ingredient | |
| KR100519191B1 (en) | Cosmetic Compositions Comprising Pau d'Arco Extract | |
| KR102305237B1 (en) | Compositions for Improving Skin Wrinkles and Skin Whitening Using an Extract of Persicaria filiforme | |
| EP3510991A1 (en) | Skin anti-aging composition containing dehydrogenated abietic acid and compound k | |
| KR20180002079A (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
| KR102573041B1 (en) | Composition for skin moisturizing comprising Capsosiphon fulvescens extract as effective component | |
| KR102106767B1 (en) | Composition for UV protection containing polysaccharides extracted from processed Panax ginseng and Green tea | |
| KR101070886B1 (en) | A composition comprising pachydictyon coriaceum extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220621 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |